BRIEF published on 02/17/2025 at 07:07, 1 year 1 month ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 year 1 month ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 1 month ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 1 month ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 2 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year 2 months ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 2 months ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 2 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce le traitement du premier patient dans l'essai de phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées Innate Pharma Tumeurs Solides Conjugué Anticorps-médicament IPH4502 Nectine-4
BRIEF published on 01/16/2025 at 07:05, 1 year 2 months ago Nouveau Bilan des Actions et Droits de Vote pour Innate Pharma Droits De Vote AMF Actions Ordinaires Structure Actionnariale Innate Pharma
BRIEF published on 01/16/2025 at 07:05, 1 year 2 months ago New Share and Voting Rights Report for Innate Pharma Common Shares Voting Rights AMF Shareholding Structure Innate Pharma
Published on 04/11/2026 at 02:00, 1 day 1 hour ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 04/11/2026 at 01:40, 1 day 1 hour ago Arctic Fox Announces Closing of Final Tranche Of Non-Brokered Private Placement
Published on 04/11/2026 at 00:30, 1 day 2 hours ago Trans Canada Gold Corp. Announces Proposed Warrant Extension
Published on 04/11/2026 at 16:45, 10 hours 32 minutes ago CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands
Published on 04/11/2026 at 16:40, 10 hours 37 minutes ago VARON Delivers Advanced Portable Oxygen Concentrator to Meet Rising Demand in Europe
Published on 04/11/2026 at 16:30, 10 hours 47 minutes ago VARON Oxygen Concentrators Meet Rising Demand for Modern Oxygen Therapy in Germany
Published on 04/10/2026 at 19:00, 1 day 8 hours ago EPIC Suisse AG – Annual General Meeting 2026 approves all proposals by the Board of Directors
Published on 04/11/2026 at 16:29, 10 hours 48 minutes ago Décès de Madame Jacqueline Himsworth, Présidente du Conseil d’administration de Manitou Group
Published on 04/11/2026 at 16:29, 10 hours 48 minutes ago Passing of Madame Jacqueline Himsworth, Chairman of the Board of Directors of Manitou Group
Published on 04/10/2026 at 18:26, 1 day 8 hours ago EURAZEO ANNOUNCES THE SUCCESS OF ITS INAUGURAL 500 MILLION EURO BOND ISSUE
